Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$25.30 +0.2%	$25.02	$22.64 ▼ $53.96	$1.20B	0.78	480,117 shs	83,497 shs
CBAY CymaBay Therapeutics	$32.48	$32.44	$7.26 ▼ $32.50	$3.73B	0.32	4.11 million shs	73 shs
IDYA IDEAYA Biosciences	$19.99 +2.2%	$17.71	$13.45 ▼ $44.42	$1.75B	0.26	1.00 million shs	475,316 shs
RCKT Rocket Pharmaceuticals	$2.60 +4.6%	$6.44	$2.19 ▼ $26.98	$279.25M	1.02	1.82 million shs	3.98 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	-1.06%	+4.55%	+3.48%	-19.78%	-39.82%
CBAY CymaBay Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
IDYA IDEAYA Biosciences	+0.72%	+2.14%	-0.96%	-3.36%	-47.88%
RCKT Rocket Pharmaceuticals	+6.44%	-62.37%	-65.36%	-73.62%	-88.16%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMPH Amphastar Pharmaceuticals	4.2648 of 5 stars	3.1	1.0	0.0	3.7	3.5	4.2	1.3
CBAY CymaBay Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IDYA IDEAYA Biosciences	3.9291 of 5 stars	3.5	2.0	0.0	4.4	3.6	1.7	0.0
RCKT Rocket Pharmaceuticals	4.7915 of 5 stars	4.2	2.0	0.0	4.7	2.0	5.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMPH Amphastar Pharmaceuticals	2.25	Hold	$32.33	27.80% Upside
CBAY CymaBay Therapeutics	0.00	N/A	N/A	N/A
IDYA IDEAYA Biosciences	2.93	Moderate Buy	$54.27	171.53% Upside
RCKT Rocket Pharmaceuticals	2.47	Hold	$22.46	765.57% Upside

Current Analyst Ratings Breakdown

Latest AMPH, CBAY, IDYA, and RCKT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/28/2025	RCKT Rocket Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
5/28/2025	RCKT Rocket Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $9.00
5/28/2025	RCKT Rocket Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $8.00
5/28/2025	RCKT Rocket Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$51.00 ➝ $19.00
5/28/2025	RCKT Rocket Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Sell
5/28/2025	RCKT Rocket Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$37.00 ➝ $8.00
5/28/2025	RCKT Rocket Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$7.00
5/28/2025	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$46.00 ➝ $17.00
5/28/2025	RCKT Rocket Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/22/2025	IDYA IDEAYA Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$63.00 ➝ $66.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMPH Amphastar Pharmaceuticals	$730.66M	1.64	$3.53 per share	7.17	$13.35 per share	1.90
CBAY CymaBay Therapeutics	$31.07M	119.92	N/A	N/A	$2.58 per share	12.59
IDYA IDEAYA Biosciences	$7M	250.08	N/A	N/A	$12.10 per share	1.65
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$5.46 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMPH Amphastar Pharmaceuticals	$137.54M	$2.76	8.45	7.69	2.19	21.80%	26.44%	11.89%	8/6/2025 (Estimated)
CBAY CymaBay Therapeutics	-$105.37M	-$0.97	N/A	N/A	N/A	N/A	-50.72%	-31.04%	N/A
IDYA IDEAYA Biosciences	-$274.48M	-$3.59	N/A	N/A	N/A	N/A	-26.74%	-25.54%	8/5/2025 (Estimated)
RCKT Rocket Pharmaceuticals	-$245.60M	-$2.63	N/A	N/A	N/A	N/A	-62.62%	-54.17%	8/4/2025 (Estimated)

Latest AMPH, CBAY, IDYA, and RCKT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.58	-$0.56	+$0.02	N/A	N/A	N/A
5/6/2025	Q1 2025	IDYA IDEAYA Biosciences	-$0.75	-$0.82	-$0.07	-$0.82	$2.10 million	N/A
5/5/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.59	-$0.56	+$0.03	-$0.56	$0.80 million	N/A
3/3/2025	Q4 2024	RCKT Rocket Pharmaceuticals	-$0.68	-$0.62	+$0.06	-$0.62	$0.03 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CBAY CymaBay Therapeutics	N/A	N/A	N/A	N/A	N/A
IDYA IDEAYA Biosciences	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMPH Amphastar Pharmaceuticals	0.82	3.43	2.61
CBAY CymaBay Therapeutics	N/A	10.96	10.96
IDYA IDEAYA Biosciences	N/A	14.97	22.93
RCKT Rocket Pharmaceuticals	0.06	6.05	6.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMPH Amphastar Pharmaceuticals	65.09%
CBAY CymaBay Therapeutics	95.03%
IDYA IDEAYA Biosciences	98.29%
RCKT Rocket Pharmaceuticals	98.39%

Insider Ownership

Company	Insider Ownership
AMPH Amphastar Pharmaceuticals	27.10%
CBAY CymaBay Therapeutics	7.00%
IDYA IDEAYA Biosciences	2.50%
RCKT Rocket Pharmaceuticals	24.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMPH Amphastar Pharmaceuticals	1,620	47.50 million	35.05 million	Optionable
CBAY CymaBay Therapeutics	101	114.72 million	106.69 million	Optionable
IDYA IDEAYA Biosciences	80	87.58 million	84.47 million	Optionable
RCKT Rocket Pharmaceuticals	240	106.79 million	65.18 million	Optionable

AMPH, CBAY, IDYA, and RCKT Headlines

Recent News About These Companies

RCKT ALERT: Levi & Korsinsky Investigates Rocket Pharmaceuticals, Inc. for Possible Securities Fraud Violations

May 29 at 11:15 AM | accessnewswire.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Cut to "Sell" at The Goldman Sachs Group

May 29 at 10:23 AM | marketbeat.com

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Rocket Pharmaceuticals, Inc. (RCKT) And Encourages Stockholders to Reach Out

May 29 at 10:00 AM | accessnewswire.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Rating Lowered by Morgan Stanley

May 29 at 8:52 AM | marketbeat.com

Leerink Partners Downgrades Rocket Pharmaceuticals (NASDAQ:RCKT) to Market Perform

May 29 at 8:52 AM | marketbeat.com

Chardan Capital Cuts Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $17.00

May 29 at 8:19 AM | marketbeat.com

Rocket Pharmaceuticals' (RCKT) Hold Rating Reaffirmed at Jefferies Financial Group

May 29 at 8:19 AM | marketbeat.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Reaches New 12-Month Low - Should You Sell?

May 29 at 6:33 AM | marketbeat.com

Bank of America Cuts Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $9.00

May 29 at 3:41 AM | americanbankingnews.com

Rocket Pharmaceuticals' (RCKT) "Hold" Rating Reiterated at Jefferies Financial Group

May 29 at 2:09 AM | americanbankingnews.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Earns Equal Weight Rating from Morgan Stanley

May 29 at 2:09 AM | americanbankingnews.com

Rocket Pharmaceuticals' (RCKT) Hold Rating Reiterated at Needham & Company LLC

May 29 at 1:37 AM | americanbankingnews.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Consensus Rating of "Moderate Buy" from Brokerages

May 29 at 1:34 AM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT

May 28 at 6:25 PM | globenewswire.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Rocket Pharmaceuticals, Inc. (RCKT) And Encourages Stockholders to Connect

May 28 at 3:15 PM | accessnewswire.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Cut to "Hold" at TD Cowen

May 28 at 12:18 PM | marketbeat.com

RCKT Stock Tanks on Patient Death in Danon Disease Study

May 28 at 12:11 PM | zacks.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Rating Lowered by Needham & Company LLC

May 28 at 11:29 AM | marketbeat.com

These Analysts Slash Their Forecasts On Rocket Pharmaceuticals

May 28 at 10:41 AM | benzinga.com

Rocket Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RCKT)

May 28 at 10:38 AM | marketbeat.com

US FDA places clinical hold on Rocket Pharma's gene therapy phase 2 trial of RP-A501 to treat Danon disease

May 28 at 5:39 AM | pharmabiz.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMPH, CBAY, IDYA, and RCKT Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

$25.30 +0.04 (+0.16%)

As of 11:40 AM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

CymaBay Therapeutics NASDAQ:CBAY

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.

IDEAYA Biosciences NASDAQ:IDYA

$19.99 +0.43 (+2.19%)

As of 11:40 AM Eastern

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Rocket Pharmaceuticals NASDAQ:RCKT

$2.60 +0.12 (+4.64%)

As of 11:40 AM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time